|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/02/20 Heron Therapeutics, Inc./DE 10-K 12/31/19 76:13M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.52M
2: EX-4.5 Instrument Defining the Rights of Security Holders HTML 38K
3: EX-23.1 Consent of Experts or Counsel HTML 26K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 33K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
23: R1 Document and Entity Information HTML 89K
54: R2 Consolidated Balance Sheets HTML 107K
75: R3 Consolidated Balance Sheets (Parenthetical) HTML 43K
33: R4 Consolidated Statements of Operations and HTML 73K
Comprehensive Loss
20: R5 Consolidated Statements of Stockholders' Equity HTML 97K
(Deficit)
51: R6 Consolidated Statements of Cash Flows HTML 120K
72: R7 Organization and Business HTML 34K
31: R8 Summary of Significant Accounting Policies HTML 102K
24: R9 Fair Value Measurements HTML 145K
25: R10 Balance Sheet Details HTML 218K
37: R11 Revenue Recognition HTML 208K
70: R12 Commitments and Contingencies HTML 52K
48: R13 Realignment of Goals and Objectives and New HTML 30K
Development Focus
26: R14 Secured Notes to Related Party HTML 35K
38: R15 Stockholders' Equity HTML 359K
71: R16 Income Taxes HTML 159K
49: R17 Other Income (Expense), Net HTML 27K
27: R18 Employee Benefit Plan HTML 28K
36: R19 Summary of Quarterly Consolidated Financial Data HTML 202K
(Unaudited)
62: R20 Summary of Significant Accounting Policies HTML 161K
(Policies)
55: R21 Summary of Significant Accounting Policies HTML 73K
(Tables)
12: R22 Fair Value Measurements (Tables) HTML 137K
39: R23 Balance Sheet Details (Tables) HTML 221K
63: R24 Revenue Recognition (Tables) HTML 198K
56: R25 Commitments and Contingencies (Tables) HTML 45K
13: R26 Stockholders' Equity (Tables) HTML 358K
40: R27 Income Taxes (Tables) HTML 155K
61: R28 Summary of Quarterly Consolidated Financial Data HTML 201K
(Unaudited) (Tables)
57: R29 Organization and Business - Additional Information HTML 27K
(Details)
53: R30 Summary of Significant Accounting Policies - HTML 41K
Percentage of Net Product Sales and Accounts
Receivable Balance (Details)
74: R31 Summary of Significant Accounting Policies - HTML 54K
Additional Information (Details)
35: R32 Summary of Significant Accounting Policies - HTML 34K
Common Stock Equivalents Excluded From Computation
of Net Loss Per Share (Details)
22: R33 Fair Value Measurements - Schedule of Financial HTML 64K
Assets Measured on a Recurring Basis (Details)
52: R34 Fair Value Measurements - Additional Information HTML 32K
(Details)
73: R35 Balance Sheet Details - Summary of Short -Term HTML 50K
Investments (Details)
34: R36 Balance Sheet Details - Additional Information HTML 43K
(Details)
21: R37 Balance Sheet Details - Schedule of Inventory HTML 36K
(Details)
50: R38 Balance Sheet Details - Schedule of Property and HTML 42K
Equipment, Net (Details)
76: R39 Balance Sheet Details - Schedule of Accrued HTML 56K
Liabilities (Details)
60: R40 Revenue Recognition - Adoption of Topic 606 HTML 97K
(Details)
65: R41 Revenue Recognition - Additional Information HTML 35K
(Details)
44: R42 Revenue Recognition - Summary of Product Sales HTML 39K
Allowance (Details)
17: R43 Commitments and Contingencies - Additional HTML 66K
Information (Details)
59: R44 Commitments and Contingencies - Summary of Future HTML 45K
Minimum Lease Payments (Details)
64: R45 Realignment of Goals and Objectives and New HTML 36K
Development Focus - Additional Information
(Details)
43: R46 Secured Notes to Related Party - Additional HTML 107K
Information (Details)
16: R47 Stockholders' Equity - Additional Information HTML 157K
(Details)
58: R48 Stockholders' Equity - Summary of Common Stock HTML 39K
Reserved for Future Issuance (Details)
66: R49 Stockholders' Equity - Summary of Stock Option HTML 46K
Activity (Details)
68: R50 Stockholders' Equity - Schedule of Options HTML 35K
Exercisable, Vested or Expected to Vest (Details)
45: R51 Stockholders' Equity - Schedule of Exercise Prices HTML 71K
And Weighted-average Remaining Contractual Lives
For Options Outstanding (Details)
18: R52 Stockholders' Equity - Summary of Stock-Based HTML 35K
Compensation Expense related to Stock-Based
Payment Awards Granted (Details)
29: R53 Stockholders' Equity - Summary of Fair Value of HTML 41K
Option Grant and ESPP Purchase Right on Grant Date
Using Black-Scholes Option Pricing Model (Details)
69: R54 Income Taxes - Schedule of Components of Income HTML 53K
Tax Expense (Benefit) (Details)
46: R55 Income Taxes - Schedule of Deferred Tax Assets and HTML 51K
Liabilities (Details)
19: R56 Income Taxes - Additional Information (Details) HTML 66K
30: R57 Income Taxes - Summary of Unrecognized Tax HTML 31K
Benefits (Details)
67: R58 Other Income (Expense), Net - Additional HTML 27K
Information (Details)
47: R59 Employee Benefit Plan - Additional Information HTML 34K
(Details)
14: R60 Summary of Quarterly Consolidated Financial Data HTML 59K
(Unaudited) - Summary of Unaudited Quarterly
Results of Operations (Details)
32: XML IDEA XML File -- Filing Summary XML 138K
42: XML XBRL Instance -- hrtx-10k_20191231_htm XML 3.66M
41: EXCEL IDEA Workbook of Financial Reports XLSX 88K
8: EX-101.CAL XBRL Calculations -- hrtx-20191231_cal XML 191K
9: EX-101.DEF XBRL Definitions -- hrtx-20191231_def XML 508K
10: EX-101.LAB XBRL Labels -- hrtx-20191231_lab XML 1.30M
11: EX-101.PRE XBRL Presentations -- hrtx-20191231_pre XML 936K
7: EX-101.SCH XBRL Schema -- hrtx-20191231 XSD 162K
28: JSON XBRL Instance as JSON Data -- MetaLinks 346± 565K
15: ZIP XBRL Zipped Folder -- 0001564590-20-007973-xbrl Zip 318K
Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Robert Hoffman, certify that:
|
1. |
I have reviewed this Annual Report on Form 10-K of Heron Therapeutics, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
(c) |
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
(d) |
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
|
5. |
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
|
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
|
Date: March 2, 2020 |
|
By: |
/s/ Robert Hoffman |
|
|
|
|
|
|
|
|
|
Chief Financial Officer and Senior Vice President, Finance (As Principal Financial Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/2/20 | 8-K | ||
| For Period end: | 12/31/19 | 5 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/12/24 Heron Therapeutics, Inc./DE 10-K 12/31/23 72:10M Donnelley … Solutions/FA 6/30/23 Heron Therapeutics, Inc./DE S-8 6/30/23 8:270K Donnelley … Solutions/FA 3/29/23 Heron Therapeutics, Inc./DE 10-K 12/31/22 73:12M Donnelley … Solutions/FA 2/28/22 Heron Therapeutics, Inc./DE 10-K 12/31/21 74:12M ActiveDisclosure/FA 2/24/21 Heron Therapeutics, Inc./DE 10-K 12/31/20 74:12M ActiveDisclosure/FA |